Torben Plesner

TL;DR: DARA SC 1,800 mg was well tolerated in relapsed/refractory multiple myeloma, with a low infusion-related reaction rate and reduced administration time, and ongoing studies are investigating DARA SC in the treatment of multipleMyeloma and other conditions.

TL;DR: This randomised, open-label, head-to-head, phase 3 study aimed to determine whether melflufen plus dexamethasone would provide a progression-free survival benefit compared with pomalidomide plus Dexameth as well as safety in patients with previously treated multiple myeloma.

TL;DR: Due to competition with the MM-produced IgG M-protein for neonatal Fc receptor protection from clearance, IgG-based monoclonal antibodies in general may have significantly higher clearance and lower concentrations in IgGMM patients compared with non-IgG MM patients.

TL;DR: Peripheral blood from 90 CLL patients was examined by light- and electron-microscopy for the occurrence of crystalline inclusions in lymphocytes, finding that inclusions persisted during antileukaemic therapy and may be related to a dysfunction in the synthesis of surface membrane-bound immunoglobulins.

TL;DR: In a patient with classical chronic lymphocytic leukemia of IgM kappa phenotype and a stable clinical course, repeated chromosome analyses of blood lymphocytes revealed the coexistence of t(14;18), a marker often associated with follicular low gradeymphocytic lymphomas, and t(2;8), a variant of the t(8;14) typically seen in Burkitt's lymphoma.